Tradestie Institutional Equity Comparison Engine

LCTX vs VTGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (3โ€“1 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin, Momentum & Technical while VTGN counters with relative strength in Options & Structure. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus VTGN at N/M Forward P/E and -2543.1% operating margin (-46.5% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against VTGN sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs VTGN N/M Fwd P/E
Growth & Margin Winner LCTX
Op Margin -280.3% vs -2543.1% ยท YoY -61.0% vs -46.5%
Momentum & Technical Winner LCTX
1Y -53.7% vs -96.0% ยท 52W Pos 4% vs 0%
Options & Structure Winner VTGN
BREAKDOWN (100th %ile IV) vs UNCLASSIFIED (71st %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
VTGN NASDAQ
Vistagen Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.19
-6.47% 1D
Market Cap $9.0M
1M Return -3.62%
1Y Return -95.97%
Forward P/E N/M
Unified AI Score
42.3 / 100 HOLD
Tech 20.0 Fund 52.0 Flow 69.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -53.67% VTGN -95.97% Spread: +42.3 pp (LCTX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LCTX Revenue VTGN Revenue LCTX Op. Margin VTGN Op. Margin Margin Edge
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M N/A -1448.4% N/A LCTX
FY2021 $0M $0M -1133.6% -1646.1% LCTX
FY2022 $10M $0M -153.2% -4308.3% LCTX
FY2023 $10M N/A -276.5% N/A LCTX
FY2024 $10M $0M -226.1% -3103.5% LCTX
FY2025 $10M $0M -251.6% -11517.1% LCTX
FY2026 N/A $0M N/A -5683.7% VTGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (9) vs VTGN (1)
Institutional Metric LCTX VTGN Criterion Row Winner
Market Capitalization Scale $212.1M $9.0M Larger Scale LCTX
Trailing P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% -46.5% Higher Growth VTGN
Operating Margin (TTM) Profitability -280.3% -2543.1% Higher Margin LCTX
Net Profit Margin Profitability 16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -144.9% Higher ROE LCTX
52-Week Range Position Momentum 4% ($1โ€“$2) 0% ($0โ€“$5) Stronger Trend LCTX
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 79% Vol 1.23ฮฒ ยท 80% Vol Lower Realized Risk LCTX
Unified Institutional Score Composite Signal 58.9 / 100 (HOLD) 42.3 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs VTGN Buy Guide
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VTGN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 71st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live VTGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor VTGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.